PREDNISOLONE SODIUM PHOSPHATE

Post-LOE

prednisolone sodium phosphate

Bausch + Lomb

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Jul 1994

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PREDNISOLONE SODIUM PHOSPHATE (prednisolone sodium phosphate) by Bausch + Lomb is clinical pharmacology prednisolone sodium phosphate causes inhibition of inflammatory response to inciting agents of mechanical, chemical, or immunological nature. Approved for the following conditions: 1, systemic lupus erythematosus, dermatomyositis (polymyositis) and 11 more indications. First approved in 1994.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Prednisolone sodium phosphate causes inhibition of inflammatory response to inciting agents of mechanical, chemical, or immunological nature. No generally accepted explanation of this steroid property has been advanced.

Indications (14)

the following conditions: 1 systemic lupus erythematosus

Worked on PREDNISOLONE SODIUM PHOSPHATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.